EXCLUSIVE. DISLOG GROUP. MONCEF BELKHAYAT: "WE'LL SEE YOU AT THE IPO IN 2026".

Dislog Group is thinking big. To pursue its development through organic and external growth, the Group plans to strengthen its equity capital by 1 MMDH in 2024. In this exclusive interview, Moncef Belkhayat, the Group's CEO, announces that he will be raising funds for successive capital increases in 2024. This is one of the reasons why he has postponed the Group's IPO until the 4th quarter of 2026. He also points out that the training of Dislog Group's top management at the Essec business school is key to the group's success.

Why didn't Méditerranéa Capital exit via the stock market, as is usually the case in this type of transaction?

The first thing to understand is the rapid evolution of the Dislog Group over the last four years. We've gone from being a simple distributor to an industrial group specializing in fmcg (fast-moving consumer goods) & healthcare. We specialize in three business units: personal and home care, food and healthcare. We are now a resilient operator, developing around a hundred brands and operating in the life economy. The training of Dislog Group's top management, at the Essec business school, is the key to the group's success.

To answer your question about Mediteranea Capital Partners (MCP), the original plan was to go public in 2024. We jointly decided to postpone the project by two to three years. MCP has been, is and will continue to be a fantastic financial partner, with a 2.5% stake in our capital and, above all, a strong presence on our board in the persons of Saad Bendidi and Hatim Ben Ahmed.

Why did you opt for SPE, which was already in your round of financing?

SPE was a shareholder in H&S Invest holding and not in Dislog Group. They left the H&S Invest board in 2021 and are returning to Dislog Group in 2024. We welcome them to our board. Our group is still linked to SPE, since Nabil Triki, their Ceo and Managing Partner, remains a director of our family holding company H&S Invest.

He's seen us evolve rapidly and transform. I think he still sees growth potential in us, and that's why they're returning to our capital with a minority stake. With this transaction, our Group will have completed around ten private equity deals over the last 15 years. We have built up a great deal of credibility with PE funds, but also with their Lp's, who have seen us grow and are starting to take an interest in financing us directly.

What will be the role and impact of the new shareholder? Had the new shareholder left the table before this operation?

With SPE and MCP in our round table, the impact will be positive, enabling us firstly to continue to use the funds to make two major new acquisitions, and secondly to prepare for an IPO on the Casablanca Stock Exchange.

In your opinion, isn't the amount of the transaction underestimated?

The amount of the transaction, which will come in the form of a capital increase, is 450 million dirhams. We will continue to raise funds to exceed one billion dirhams in capital raising by 2024. We'll need to consolidate and integrate the companies we acquire, and prove our ability to create more value by putting them on the right track.

What explains the delay in Dislog's IPO? The market seems eager to welcome you...

We're just as eager to enter the market. We are in a phase of growth and development. Our financial advisors recommend that we stabilize our perimeter before making this IPO.

After the two new acquisitions planned for 2024 thanks to the SPE and other fund-raising campaigns, our management - whom I'd like to salute and thank - will consolidate our achievements and stabilize our scope of intervention in the three business units of food, hygiene and health.
Once again, we have become a resilient, brand-building industrial operator operating in the life economy. Our equity story is increasingly clear and attractive. We're delighted. See you then at the IPO in 2026, in the company of MCP, SPE and other institutional investors, I hope.

Moulay Ahmed Belghiti / ECO Inspirations

source : Exclusive. Dislog Group. Moncef Belkhayat: "Rendez-vous for the IPO in 2026" - LesEco.ma

Share

Empowering Your Laboratories with Excellence

Since 1992, Megaflex SARL has established itself as a key force in the medical sector in Morocco. We are more than just a supplier: we are the strategic partner that supports laboratories in their pursuit of innovation, efficiency, and performance.

Market leader: Over 30 years of expertise and a reputation built on quality, reliability, and innovation.
Global partnerships: We collaborate with the best international brands to provide cutting-edge technology.
National presence: Extensive coverage and dedicated customer service to support you every step of the way.

At Megaflex, we believe every laboratory deserves solutions that combine advanced technology with ease of use. Our mission is clear: to provide you with the tools to excel in your field while optimizing your resources.

For further information:
www.megaflex.ma

25 Years Serving the Pharmaceutical Industry

With 25 years of presence in the Moroccan market, FARMALAC has grown into a dynamic company specializing in the research, development, and distribution of raw materials and packaging components . We collaborate with renowned partners in the pharmaceutical industry and take pride in the journey we’ve built.

Today, FARMALAC is a well-established company with recognized expertise and a loyal customer base. Thanks to our deep understanding of the Moroccan market, we are confident in our ability to meet our clients’ specific needs by sourcing new products and identifying new suppliers.

FARMALAC follows a strict partner selection policy, choosing only companies that offer high-quality products certified under ISO 9001 and ISO 15378 standards. This ensures that our clients receive materials that comply with international Good Manufacturing Practices (GMP).

For further information:
www.farmalac.ma

MEDICAL EXELLENCE

We take pride in being your trusted supplier of medical devices, particularly cardiology equipment. Since 2009, we’ve been present in the Moroccan and African markets, committed to delivering the latest technologies to support healthcare professionals in their vital work.

At AFROBIOMEDIC, we are passionate about our mission to provide innovative medical solutions that improve patients’ quality of life. With in-depth expertise in cardiology, we offer cutting-edge equipment designed to meet the highest professional standards.

We work with the industry’s leading manufacturers to ensure the quality and reliability of our products. Our skilled pre-sales and after-sales service teams are also here to help you deliver personalized care to your patients.

We sincerely thank all our clients and partners for their continued trust and support. We look forward to continuing our collaboration to provide outstanding medical solutions.

For further information:
www.afrobiomedic.com

Dislog Group operates in the healthcare sector through a strong presence in the pharmaceutical industry. A pillar of Morocco’s pharmaceutical landscape, KPH Pharmaceutical Laboratories are recognized leaders in the manufacturing of dermo-cosmetic products, with iconic brands such as Kaline and Argapur, alongside a wide range of pharmaceutical products and dietary supplements.

KPH Pharmaceutical Laboratories’ production spans multiple therapeutic areas, including dermatology, gynecology, pediatrics, pulmonology, surgery, internal medicine, and general medicine. The laboratories offer innovative solutions to meet the needs of both patients and healthcare professionals.

Modern pharmaceutical laboratories

Our laboratories are equipped with cutting-edge technology and adhere to the highest international standards. All medicines are manufactured following rigorous global pharmaceutical guidelines. KPH Pharmaceutical Laboratories operate a 2,800 m² facility that complies with European standards, Good Distribution Practices (GDP), and Health, Safety & Environment (HSE) requirements.

products & services

FULL SERVICE PROVIDER

KPH Laboratories specialize in the design and production of dietary supplements and cosmetics. Our expertise ensures high-quality manufacturing that meets the expectations of our clients and partners.
visit the site

GAME PRIVATE LABEL

We offer a wide selection of white-label dietary supplements, developed in line with market trends and fully compliant with regulations.
visit the site

LOGISTICS

Our logistics team ensures the procurement and delivery of medicines to pharmacies. We follow an accredited logistics model with strict control across the entire value chain.
visit the site

DISTRIBUTION

Our modern distribution center includes specialized storage zones, five cold rooms, and a secured containment room. We ship over 70 million units annually to wholesalers, hospitals, clinics, and pharmacies across Morocco and internationally.
visit the site

DRUGS

Our medical range addresses essential healthcare needs. It includes POLYFER, an iron syrup dosed at 50 mg/5 ml in a 150 ml bottle, and AMYKON, an antifungal cream in a 15g tube — both developed according to the highest pharmaceutical standards.
visit the site

DIETARY SUPPLEMENTS

To support optimal daily health, we offer a comprehensive range that includes COMBIVIT in sugar-free effervescent tablets, PRONATAL in 375 mg capsules, and STRATH, available as 50g tablets or a 125 ml fortifying syrup.
visit the site

PARAMEDICAL PRODUCTS

Our parapharmaceutical line offers targeted solutions for various needs: SIACEN for skin repair and healing, SOLUELASTINE for stretch mark treatment, and SCARGEL, specially formulated for scar care.
visit the site

DERMO-COSMETICS

Our dermocosmetic range includes Kaline, designed for sensitive skin, and Argapur, formulated with pure argan oil. Each product is developed to the highest quality standards, combining effectiveness, safety, and user comfort.
visit the site
OUR CERTIFICATIONS

Founded in 1999, Steripharma is one of the leading Moroccan players in the field of generic medicines.
For over 20 years, Steripharma has established itself in Morocco, the Maghreb, and across the African continent as a recognized contract manufacturer, developer, and distributor.

Our product range covers 90% of major therapeutic areas, offering both retail and hospital medications.

Steripharma employs over 200 collaborators across various areas of expertise.

THERAPEUTIC AREAS

Dental

Pharmaceutical solutions dedicated to oral health, designed to meet the standards of professionals in the sector.
visit the site

Cardiology and blood system

Essential drugs for the management of cardiovascular and hematological diseases.
visit the site

Infectiology and parasitology

Rigorous treatment of bacterial, viral and parasitic infections, in line with public health needs.
visit the site

Respiratory system

Effective treatments for acute and chronic respiratory ailments, focused on the patient's well-being.
visit the site

Ophthalmology

Treatments adapted to ocular pathologies, combining tolerance and therapeutic efficacy.
visit the site

Dermatology

Targeted range of dermatological treatments covering the most common skin conditions.
visit the site

Digestive system

Products adapted to the most common gastrointestinal disorders and metabolic imbalances.
visit the site

CNS (Central Nervous System)

Therapeutic solutions for neurological and musculoskeletal disorders, focused on improving mobility and comfort.
visit the site
OUR CERTIFICATIONS